版本:
中国

BRIEF-Novartis Pharmaceuticals Canada says combination treatment tafinlar plus mekinist approved by Health Canada

June 15 Novartis Ag

* Novartis Pharmaceuticals Canada - combination treatment tafinlar plus mekinist approved by Health Canada to treat braf V600-positive metastatic NSCLC after prior systemic therapy Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐